South Korea-based Celltrion has completed a re-submission to the US Food and Drug Administration (FDA) seeking approval for CT-P6, a proposed mAb biosimilar to cancer drug Herceptin.
It was reported yesterday that the company had submitted its abbreviated Biologics License Applications(aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received complete response letters from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea.
The firm had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalised within six months from the resubmission, so the company expects the approval for the United States market of the two proposed biosimilars within this calendar year.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT